Difference between revisions of "Part:BBa K3335003"
Line 28: | Line 28: | ||
<p>Figure.3 Absolute quantification of KRAS siRNA</p> | <p>Figure.3 Absolute quantification of KRAS siRNA</p> | ||
<p>At the same time, We detected siRNA in exosomes produced by HEK293T cells, confirmed that siRNA could be properly wrapped into exosomes, and prepared for its role (Figure.2).</p> | <p>At the same time, We detected siRNA in exosomes produced by HEK293T cells, confirmed that siRNA could be properly wrapped into exosomes, and prepared for its role (Figure.2).</p> | ||
− | <p>According to the absolute quantification of KRAS siRNA, we found that the amount of siRNA in HEK293T cells is | + | <p>According to the absolute quantification of KRAS siRNA, we found that the amount of siRNA in HEK293T cells is 9.138E-02 pM, the amount of siRNA in exosome is 2.848E-03 pM. The exosome siRNA is equivalent to 3.11% of the siRNA concentration in the cell.</p> |
<!-- --> | <!-- --> | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K3335003 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3335003 SequenceAndFeatures</partinfo> |
Revision as of 18:12, 25 October 2020
We used it to express iRGD-Lamp2b and siRNA targeted at KRAS
Lung cancer is the major cause of cancer-related deaths globally. Mutant KRAS is a feature of 15%–50% of lung cancer cases[1]. Unfortunately, although much effort has been spent on searching for small molecule inhibitors of KRAS, KRAS gene has proven extraordinarily difficult to target by current pharmacological agents.
This year we developed an alternative strategy to silence the so-called untargetable and undruggable KRAS gene by employing exosome-mediated siRNA delivery.At the same time, we used iRGDLamp2b to achieve exosome targeting. Particularly, we reprogrammed cells to simultaneously express KRAS siRNA and Lamp2b. Lamp2b is an exosomal membrane protein, in fusion with a tumor-penetrating internalizing RGD (iRGD) peptide (CRGDKGPDC), and then produce the tumor-targeting exosomes as KRAS siRNA delivery system.[1]
With this system, we can target tumor cells and deliver siRNA.
[1]Yu Zhou et al.,Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth. ExRNA,2019.
Usage and Biology
Functional Parameters
KRAS siRNA overexpressed in HEK293T cell and exosome
First, we detected the correct expression of KRAS siRNA through RT-QPCR to ensure that sufficient targeted siRNA could be produced in cell. CMV-iRGD-siRK is this part. CMV-iRGD-siRP+C+K is a Composite part.
Figure.1 KRAS siRNA is overexpressed is HEK293T cell
Figure2. KRAS siRNA is overexpressed in exosome
Figure.3 Absolute quantification of KRAS siRNA
At the same time, We detected siRNA in exosomes produced by HEK293T cells, confirmed that siRNA could be properly wrapped into exosomes, and prepared for its role (Figure.2).
According to the absolute quantification of KRAS siRNA, we found that the amount of siRNA in HEK293T cells is 9.138E-02 pM, the amount of siRNA in exosome is 2.848E-03 pM. The exosome siRNA is equivalent to 3.11% of the siRNA concentration in the cell.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 1277
- 1000COMPATIBLE WITH RFC[1000]